Manchester Centre for Health Economics, The University of Manchester, Manchester, UK
Manchester Centre for Health Economics, The University of Manchester, Manchester, UK.
Heart. 2023 May 26;109(12):913-920. doi: 10.1136/heartjnl-2021-320459.
Centre-based cardiac rehabilitation (CR) is recognised as cost-effective for individuals following a cardiac event. However, home-based alternatives are becoming increasingly popular, especially since COVID-19, which necessitated alternative modes of care delivery. This review aimed to assess whether home-based CR interventions are cost-effective (vs centre-based CR).
Using the MEDLINE, Embase and PsycINFO databases, literature searches were conducted in October 2021 to identify full economic evaluations (synthesising costs and effects). Studies were included if they focused on home-based elements of a CR programme or full home-based programmes. Data extraction and critical appraisal were completed using the NHS EED handbook, Consolidated Health Economic Evaluation Reporting Standards and Drummond checklists and were summarised narratively. The protocol was registered on the PROSPERO database (CRD42021286252).
Nine studies were included in the review. Interventions were heterogeneous in terms of delivery, components of care and duration. Most studies were economic evaluations within clinical trials (8/9). All studies reported quality-adjusted life years, with the EQ-5D as the most common measure of health status (6/9 studies). Most studies (7/9 studies) concluded that home-based CR (added to or replacing centre-based CR) was cost-effective compared with centre-based options.
Evidence suggests that home-based CR options are cost-effective. The limited size of the evidence base and heterogeneity in methods limits external validity. There were further limitations to the evidence base (eg, limited sample sizes) that increase uncertainty. Future research is needed to cover a greater range of home-based designs, including home-based options for psychological care, with greater sample sizes and the potential to acknowledge patient heterogeneity.
以中心为基础的心脏康复(CR)被认为对心脏病发作后的个体具有成本效益。然而,家庭为基础的替代方案越来越受欢迎,尤其是自 COVID-19 以来,这需要替代的护理提供方式。本综述旨在评估家庭为基础的 CR 干预措施是否具有成本效益(与以中心为基础的 CR 相比)。
使用 MEDLINE、Embase 和 PsycINFO 数据库,于 2021 年 10 月进行文献检索,以确定全经济评估(综合成本和效果)的文献。如果研究集中于 CR 计划的家庭为基础元素或全家庭为基础的计划,则将其纳入研究。使用 NHS EED 手册、统一健康经济评估报告标准和 Drummond 清单进行数据提取和关键评估,并进行叙述性总结。该方案已在 PROSPERO 数据库(CRD42021286252)中注册。
本综述纳入了 9 项研究。干预措施在交付、护理内容和持续时间方面存在异质性。大多数研究是临床试验内的经济评估(9/9)。所有研究均报告了质量调整生命年,EQ-5D 是健康状况最常用的衡量标准(6/9 项研究)。大多数研究(7/9 项研究)得出结论,与以中心为基础的方案相比,家庭为基础的 CR(附加或替代以中心为基础的 CR)具有成本效益。
有证据表明,家庭为基础的 CR 选择具有成本效益。证据基础的规模有限和方法的异质性限制了外部有效性。证据基础还存在其他限制因素(例如,样本量有限),这增加了不确定性。需要进一步的研究来涵盖更广泛的家庭为基础的设计,包括家庭为基础的心理护理选择,具有更大的样本量和承认患者异质性的潜力。